Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era

Elizabeth A Platz, Michael N. Pollak, Michael F. Leitzmann, Meir J. Stampfer, Walter C. Willett, Edward Giovannucci

Research output: Contribution to journalArticle

Abstract

Objective: The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer detected in the PSA era. Methods: We identified 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer. Results: Men with higher concentrations of IGF-1 (comparing extreme quartiles OR=1.37, 95% CI 0.92-2.03, p-trend=0.05) and IGFBP-3 (OR=1.62, 95% CI 1.07-2.46, p-trend=0.08) had a higher risk of prostate cancer. After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR=1.17, 95% CI 0.69-1.99, p-trend=0.29) and IGFBP-3 (OR=1.40, 95% CI 0.80-2.44, p-trend=0.56). We found no significant association of IGF-1 with regionally invasive or metastatic (≥T3b, N1, or M1) prostate cancer, although the number of these cases was small (n=42). Conclusions: Our findings for IGF-1 and prostate cancer diagnosed in the PSA era are similar to most previous studies, albeit weaker in magnitude. Our suggestive positive findings for IGFBP-3 are similar to some studies, but in direct contrast to others.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalCancer Causes and Control
Volume16
Issue number3
DOIs
StatePublished - Apr 2005

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Somatomedins
Prostatic Neoplasms
Odds Ratio
Confidence Intervals
Men's Health
Insulin-Like Growth Factor Binding Protein 1
Logistic Models
Enzyme-Linked Immunosorbent Assay
Prospective Studies

Keywords

  • Cohort study
  • Insulin-like growth factor
  • Prostate cancer
  • Risk

ASJC Scopus subject areas

  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. / Platz, Elizabeth A; Pollak, Michael N.; Leitzmann, Michael F.; Stampfer, Meir J.; Willett, Walter C.; Giovannucci, Edward.

In: Cancer Causes and Control, Vol. 16, No. 3, 04.2005, p. 255-262.

Research output: Contribution to journalArticle

Platz, Elizabeth A ; Pollak, Michael N. ; Leitzmann, Michael F. ; Stampfer, Meir J. ; Willett, Walter C. ; Giovannucci, Edward. / Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. In: Cancer Causes and Control. 2005 ; Vol. 16, No. 3. pp. 255-262.
@article{093ebce3e7594f67aa49b68aeae93658,
title = "Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era",
abstract = "Objective: The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer detected in the PSA era. Methods: We identified 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios (OR) and 95{\%} confidence intervals (CI) of prostate cancer. Results: Men with higher concentrations of IGF-1 (comparing extreme quartiles OR=1.37, 95{\%} CI 0.92-2.03, p-trend=0.05) and IGFBP-3 (OR=1.62, 95{\%} CI 1.07-2.46, p-trend=0.08) had a higher risk of prostate cancer. After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR=1.17, 95{\%} CI 0.69-1.99, p-trend=0.29) and IGFBP-3 (OR=1.40, 95{\%} CI 0.80-2.44, p-trend=0.56). We found no significant association of IGF-1 with regionally invasive or metastatic (≥T3b, N1, or M1) prostate cancer, although the number of these cases was small (n=42). Conclusions: Our findings for IGF-1 and prostate cancer diagnosed in the PSA era are similar to most previous studies, albeit weaker in magnitude. Our suggestive positive findings for IGFBP-3 are similar to some studies, but in direct contrast to others.",
keywords = "Cohort study, Insulin-like growth factor, Prostate cancer, Risk",
author = "Platz, {Elizabeth A} and Pollak, {Michael N.} and Leitzmann, {Michael F.} and Stampfer, {Meir J.} and Willett, {Walter C.} and Edward Giovannucci",
year = "2005",
month = "4",
doi = "10.1007/s10552-004-3484-8",
language = "English (US)",
volume = "16",
pages = "255--262",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era

AU - Platz, Elizabeth A

AU - Pollak, Michael N.

AU - Leitzmann, Michael F.

AU - Stampfer, Meir J.

AU - Willett, Walter C.

AU - Giovannucci, Edward

PY - 2005/4

Y1 - 2005/4

N2 - Objective: The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer detected in the PSA era. Methods: We identified 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer. Results: Men with higher concentrations of IGF-1 (comparing extreme quartiles OR=1.37, 95% CI 0.92-2.03, p-trend=0.05) and IGFBP-3 (OR=1.62, 95% CI 1.07-2.46, p-trend=0.08) had a higher risk of prostate cancer. After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR=1.17, 95% CI 0.69-1.99, p-trend=0.29) and IGFBP-3 (OR=1.40, 95% CI 0.80-2.44, p-trend=0.56). We found no significant association of IGF-1 with regionally invasive or metastatic (≥T3b, N1, or M1) prostate cancer, although the number of these cases was small (n=42). Conclusions: Our findings for IGF-1 and prostate cancer diagnosed in the PSA era are similar to most previous studies, albeit weaker in magnitude. Our suggestive positive findings for IGFBP-3 are similar to some studies, but in direct contrast to others.

AB - Objective: The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer detected in the PSA era. Methods: We identified 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer. Results: Men with higher concentrations of IGF-1 (comparing extreme quartiles OR=1.37, 95% CI 0.92-2.03, p-trend=0.05) and IGFBP-3 (OR=1.62, 95% CI 1.07-2.46, p-trend=0.08) had a higher risk of prostate cancer. After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR=1.17, 95% CI 0.69-1.99, p-trend=0.29) and IGFBP-3 (OR=1.40, 95% CI 0.80-2.44, p-trend=0.56). We found no significant association of IGF-1 with regionally invasive or metastatic (≥T3b, N1, or M1) prostate cancer, although the number of these cases was small (n=42). Conclusions: Our findings for IGF-1 and prostate cancer diagnosed in the PSA era are similar to most previous studies, albeit weaker in magnitude. Our suggestive positive findings for IGFBP-3 are similar to some studies, but in direct contrast to others.

KW - Cohort study

KW - Insulin-like growth factor

KW - Prostate cancer

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=21244456541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244456541&partnerID=8YFLogxK

U2 - 10.1007/s10552-004-3484-8

DO - 10.1007/s10552-004-3484-8

M3 - Article

C2 - 15947877

AN - SCOPUS:21244456541

VL - 16

SP - 255

EP - 262

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 3

ER -